NASDAQ: OSUR
Orasure Technologies Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their OSUR stock forecasts and price targets.

Forecast return on equity

Is OSUR forecast to generate an efficient return?

Company
N/A
Industry
8.88%
Market
80.27%

Forecast return on assets

Is OSUR forecast to generate an efficient return on assets?

Company
N/A
Industry
5.41%

OSUR earnings per share forecast

What is OSUR's earnings per share in the next 2 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$0.56
Avg 2 year Forecast
-$0.32

OSUR revenue forecast

What is OSUR's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$136.3M-26.68%
Avg 2 year Forecast
$147.9M-20.42%
Avg 3 year Forecast
$159.8M-14.01%
OSUR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

OSUR revenue growth forecast

How is OSUR forecast to perform vs Medical Instruments & Supplies companies and vs the US market?

Company
-4.92%
Industry
9.75%
Market
10.07%
OSUR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
OSUR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

OSUR vs Medical Stocks

TickerPricePrice TargetUp/downsideConsensus
OSUR$2.99N/AN/A
NYXH$6.14$15.00+144.30%Strong Buy
PDEX$65.68$52.00-20.83%Buy
AVR$4.95$16.50+233.33%Strong Buy
ZTEK$1.66N/AN/A

Orasure Technologies Stock Forecast FAQ

What is OSUR's earnings growth forecast for 2025-2026?

(NASDAQ: OSUR) Orasure Technologies's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Instruments & Supplies industry's average forecast earnings growth rate of 17.64%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.59%.

Orasure Technologies's earnings in 2025 is -$19,500,000.On average, 2 Wall Street analysts forecast OSUR's earnings for 2025 to be -$41,514,073, with the lowest OSUR earnings forecast at -$49,368,086, and the highest OSUR earnings forecast at -$33,660,059.

In 2026, OSUR is forecast to generate -$23,936,042 in earnings, with the lowest earnings forecast at -$36,652,064 and the highest earnings forecast at -$11,220,020.

If you're new to stock investing, here's how to buy Orasure Technologies stock.

What is OSUR's revenue growth forecast for 2025-2027?

(NASDAQ: OSUR) Orasure Technologies's forecast annual revenue growth rate of -4.92% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 9.75%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.

Orasure Technologies's revenue in 2025 is $185,827,000.On average, 2 Wall Street analysts forecast OSUR's revenue for 2025 to be $10,191,891,849, with the lowest OSUR revenue forecast at $10,017,981,545, and the highest OSUR revenue forecast at $10,365,802,154. On average, 2 Wall Street analysts forecast OSUR's revenue for 2026 to be $11,061,817,373, with the lowest OSUR revenue forecast at $10,994,123,254, and the highest OSUR revenue forecast at $11,129,511,491.

In 2027, OSUR is forecast to generate $11,952,312,932 in revenue, with the lowest revenue forecast at $11,952,312,932 and the highest revenue forecast at $11,952,312,932.

What is OSUR's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: OSUR) forecast ROA is N/A, which is lower than the forecast US Medical Instruments & Supplies industry average of 5.41%.

What is OSUR's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: OSUR) Orasure Technologies's current Earnings Per Share (EPS) is -$0.26. On average, analysts forecast that OSUR's EPS will be -$0.56 for 2025, with the lowest EPS forecast at -$0.66, and the highest EPS forecast at -$0.45. In 2026, OSUR's EPS is forecast to hit -$0.32 (min: -$0.49, max: -$0.15).

What is OSUR's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: OSUR) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.